Skip to main content
. 2012 Oct 24;2012:294730. doi: 10.1155/2012/294730

(a) Demographic and practice characteristicsa,b.

   PCPsc  
n (column %)d  
(95%  CI)e
Naturopaths  
n (column %)d  
(95%  CI)e
OB-GYNs  
n (column %)d
(95%  CI)e
Specialistsf
n (column %)d  
(95%  CI)e
Total 363 (30.0%) 216 (17.9%) 333 (27.5%) 297 (24.6%)
(27.5%–32.7%) (15.8%–20.1%) (25.1%–30.1%) (22.2%–27.1%)

Mean age (years) 357 (48.0 yrs) 211  (43.5 yrs) 329 (47.8 yrs) 288 (47.6 yrs)
(26 yrs–76 yrs)g ( 28 yrs–70 yrs) g (27 yrs–80 yrs)g (27 yrs–79 yrs)g

Number of patients seen per week

<50 104 (28.8%) 185 (86.4%) 103 (31.0%) 127 (43.3%)
(24.4%–33.8%) (81.2%–90.4%) (26.3%–36.2%) (37.8%–49.1%)
50–75 129 (35.7%) 25 (11.7%) 126 (38.0%) 121 (41.3%)
(31.0%–40.9%) (8.0%–16.7%) (32.9%–43.3%) (35.8%–47.0%)
>75 127 (35.5%) 4 (1.9%) 103 (31.0%) 45 (15.4%)
(30.5%–40.4%) (0.7%–4.9%) (26.3%–36.2%) (11.7%–20.0%)

Recommend BOCh  
screening to patients w/o cancer
394 (97.5%) 196 (92.0%) 326 (98.5%) 187 (63.6%)
(95.2%–98.7%) (87.5%–95.0%) (96.4%–99.4%) (57.9%–68.9%)

Recommend CRCi  
screening to patients w/o cancer
355 (98.3%) 204 (95.8%) 316 (94.9%) 275 (93.5%)
(96.4%–99.3%) (92.1%–97.8%) (91.9%–96.8%) (90.1%–95.8%)

Treat patients for BOCh 47 (13.1%) 79 (36.9%) 53 (16.1%) 172 (58.3%)
(10.0%–17.0%) (30.7%–43.6%) (12.5%–20.4%) (52.6%–63.8%)

Treat patients for CRCi 48 (13.3%) 63 (29.4%) 0 241 (81.1%)
(10.1%–17.2%) (23.7%–35.9%) (76.3%–85.2%)

aCategory totals may be less than the total number of respondents, due to missing values.

bBolded estimates indicate significant findings.

cPCPs: primary care providers which include family physicians, internal medicine physicians, primary care nurse practitioners, and primary care physician assistants.

dThe column % reflects the percent responding within each practice category.

eCI: confidence interval.

fSpecialists consisted of surgeons, colorectal surgeons, general surgeons, gastroenterologists, oncologists, and gynecologic oncologists.

gRange in years.

hBOC: breast and ovarian cancer.

iCRC: colorectal cancer.